-
CDC: All baby boomers should get hepatitis C test
Read More ...Forward to Friend ...Comments...
-
CMS innovation center awards 26 grants worth $122.6M
Read More ...Forward to Friend ...Comments...
-
Patients responsible for 26% of health bills in 2011 vs 21% in '09
Read More ...Forward to Friend ...Comments...
-
PwC: Pharma comes up short convincing payers of cost efficacy
Read More ...Forward to Friend ...Comments...
-
Senate could vote next week to give FDA broader regs authority
Read More ...Forward to Friend ...Comments...
-
Supercomputers make biopharma a super investment
Read More ...Forward to Friend ...Comments...
-
Delhi's drug regs OD: focus should be on real problem, fake meds
Read More ...Forward to Friend ...Comments...
-
Domestic pharmas join critics of India's drug price cap proposals
Read More ...Forward to Friend ...Comments...
-
Euro RSCG: I used to say 95% of all advertising is crap. It still is..
Read More ...Forward to Friend ...Comments...
-
Four ways to make medicine (pay) more like Facebook
Read More ...Forward to Friend ...Comments...
-
Health care consolidation and competition after PPACA
Read More ...Forward to Friend ...Comments...
-
Looking back at two years of social media in health care
Read More ...Forward to Friend ...Comments...
-
McKinsey: 5 questions to ask to measure marketing's worth
Read More ...Forward to Friend ...Comments...
-
NIH ID's 40 approved drugs showing promise for rare bone Ca
Read More ...Forward to Friend ...Comments...
-
PhRMA: World trying to lure biopharmaceutical R&D from US
Read More ...Forward to Friend ...Comments...
-
White House issues statement of support for PDUFA bill
Read More ...Forward to Friend ...Comments...
-
Cancer Genetics postpones $48M IPO amid Facebook frenzy
Read More ...Forward to Friend ...Comments...
-
GSK relations w/ 3 cos show one deal can lead to another, or not
Read More ...Forward to Friend ...Comments...
-
Intel: Teen wins fair w/ early stage, noninv pancreatic Ca test
Read More ...Forward to Friend ...Comments...
-
PDR & iHealth drug safety certification program for EHRs & e-Rxs
Read More ...Forward to Friend ...Comments...
-
Pfizer recalls Advil Liqui-Gel over concerns of unusual odor
Read More ...Forward to Friend ...Comments...
-
Polymathism is largely untapped force in business practice
Read More ...Forward to Friend ...Comments...
-
Silence & Alnylam updates on RNAi candidates for solid Ca's
Read More ...Forward to Friend ...Comments...
-
Spectral Diagnostics opens toraymyxin Ph 3 to cut sepsis death
Read More ...Forward to Friend ...Comments...
-
There are ways plans can curtail copay coupons' use
Read More ...Forward to Friend ...Comments...
-
Ventricular 'parachute' has big impact on HF outcomes
Read More ...Forward to Friend ...Comments...
-
$16M of new NIH 2012 Alzheimers $50M to Roche in Columbia
Read More ...Forward to Friend ...Comments...
-
Accelerating gene driven dis is due to "weak purifying selection"
Read More ...Forward to Friend ...Comments...
-
Accelerating part 2: Rare mutations cause dis, complicate R&D
Read More ...Forward to Friend ...Comments...
-
AMA: How external pressures affect physicians' prescribing
Read More ...Forward to Friend ...Comments...
-
BG Med files for expanded indication of Galectin-3 test in HF
Read More ...Forward to Friend ...Comments...
-
Biogen, Elan: Greatest increase in Tysabri PML risk after two yrs
Read More ...Forward to Friend ...Comments...
-
Bioquell to benefit from risks of cross-contamination in bio-mfrg
Read More ...Forward to Friend ...Comments...
-
Canada OK's Osiris' Prochymal. 1st stem cell Tx for systemic dis
Read More ...Forward to Friend ...Comments...
-
Drugmakers weigh emergency supply plan for Greece
Read More ...Forward to Friend ...Comments...
-
GSK's top North American exec dips toe into blogosphere
Read More ...Forward to Friend ...Comments...
-
Kleiner Perkins backs early-stage biotechs with $525M fund
Read More ...Forward to Friend ...Comments...
-
Mutations in STAT3 are common in LGLL suggesting causation
Read More ...Forward to Friend ...Comments...
-
No scientific evidence suggests we use only 10% of our brains
Read More ...Forward to Friend ...Comments...
-
Shareholder spring is offering even more sport than usual
Read More ...Forward to Friend ...Comments...
-
Yale: US approves drugs faster than Europe and Canada
Read More ...Forward to Friend ...Comments...
-
Allergan to build R&D plant, add 400 jobs in New Jersey
Read More ...Forward to Friend ...Comments...
-
Antibiotics still beat probiotics at preventing UTIs
Read More ...Forward to Friend ...Comments...
-
Avraham opens Ph 2 for ladostigil in mild cognitive impairment
Read More ...Forward to Friend ...Comments...
-
Cataloging wounds of war in Afghanistan to help heal them
Read More ...Forward to Friend ...Comments...
-
CDC's 1999-2008 US Cancer Statistics (USCS) released
Read More ...Forward to Friend ...Comments...
-
Could GSK's BRAF inh top combo Roche's Zelboraf in melanoma?
Read More ...Forward to Friend ...Comments...
-
Coventry ends deal to cover Sequenom's Down Syndrome test
Read More ...Forward to Friend ...Comments...
-
Doubt cast on the 'good' in 'good cholesterol'
Read More ...Forward to Friend ...Comments...
-
Fall River, MA breaks ground on Biomanufacturing Accelerator
Read More ...Forward to Friend ...Comments...
-
Fate of 'uninsurables' hinges on Supreme Court
Read More ...Forward to Friend ...Comments...
-
New Hampshire approves bill for tracking Rx drug abuse
Read More ...Forward to Friend ...Comments...
-
Percentage of girls completing all 3 doses of HPV vax dropping
Read More ...Forward to Friend ...Comments...
-
Stopping fake drugs in Pakistan too late for victims
Read More ...Forward to Friend ...Comments...
-
There's an elephant in LR: R&D cuts akin to eating seed corn
Read More ...Forward to Friend ...Comments...
-
VC model: "We vave met the enemy... and he is us"
Read More ...Forward to Friend ...Comments...
-
5 processes cause breast Ca mutations; One, a 'sudden storm'
Read More ...Forward to Friend ...Comments...
-
Aargh!! J$J recalls continue with Imodium OTC antidiarrheal
Read More ...Forward to Friend ...Comments...
-
At 2 years old, she's already a chemo survivor & medical pioneer
Read More ...Forward to Friend ...Comments...
-
Broad Inst: Raising HDL of little benefit. CETP's coupe de grace?
Read More ...Forward to Friend ...Comments...
-
CETP discoverer hangs on to glimmer of hope
Read More ...Forward to Friend ...Comments...
-
How did child psychiatry become 'ped psychopharmacology'?
Read More ...Forward to Friend ...Comments...
-
Human Genome adopts poison pill with 15% trigger to fight GSK
Read More ...Forward to Friend ...Comments...
-
Human Genome Sciences claims talks with other "major" cos
Read More ...Forward to Friend ...Comments...
-
Pfizer ALK blkr, Xalkori: "Really extraordinary" in COG study
Read More ...Forward to Friend ...Comments...
-
Plavix expiry will be brutal. Multiple generic entries
Read More ...Forward to Friend ...Comments...
-
Plavix expiry won't help Lilly, AstraZeneca with Effient, Brilinta
Read More ...Forward to Friend ...Comments...
-
Rosetta Genomics gets 1st Medicare coverage of microRNA Dx
Read More ...Forward to Friend ...Comments...
-
SEC probes Dendreon amid shareholder lawsuits
Read More ...Forward to Friend ...Comments...
-
Agilent to buy Dako diagnostics for $2.2B in its biggest ever deal
Read More ...Forward to Friend ...Comments...
-
Belt & suspenders approach needed to manage IP risk in China
Read More ...Forward to Friend ...Comments...
-
CoverMyMeds plugs in to NaviNet's communications network
Read More ...Forward to Friend ...Comments...
-
Credibility vs Control: Core difference between PR & advertising
Read More ...Forward to Friend ...Comments...
-
Driver mutations advantage to breast Ca cells for oncogenesis
Read More ...Forward to Friend ...Comments...
-
Elsevier editor resigns: Can't put profits over research access
Read More ...Forward to Friend ...Comments...
-
Is Morgan Stanley's ReachOut Health abusing kids, soaking US?
Read More ...Forward to Friend ...Comments...
-
Lancet: NHS 'should consider giving statins to healthy people'
Read More ...Forward to Friend ...Comments...
-
Pfizer, GSK, J&J grab ASCO spotlight targeting Ca genetics
Read More ...Forward to Friend ...Comments...
-
Physicians are often unfamiliar with long-term risks of chemo
Read More ...Forward to Friend ...Comments...
-
Sales forces shrank in 2011, but not everywhere
Read More ...Forward to Friend ...Comments...
-
Ambit & Teva get FDA IND for BRAF (V600E) inh, CEP-32496
Read More ...Forward to Friend ...Comments...
-
ArQule, Daiichi Sankyo's tivantinib wins in c-Met liver Ca Ph 2
Read More ...Forward to Friend ...Comments...
-
Auxilium says new patent protects Testim gel to 2023
Read More ...Forward to Friend ...Comments...
-
Dendreon's Provenge works best for patients with low PSA
Read More ...Forward to Friend ...Comments...
-
J&J's Zytiga can eliminate high-risk prostate Ca if given early
Read More ...Forward to Friend ...Comments...
-
Kythera Bio files plans for IPO of $86.3M to advance ATX-101
Read More ...Forward to Friend ...Comments...
-
No industry despises IT (accountability) as much as health care
Read More ...Forward to Friend ...Comments...
-
Novartis' NVA237 superior to placebo over 1 year in COPD
Read More ...Forward to Friend ...Comments...
-
Popular antibiotic, azithromycin, may raise sudden death risk
Read More ...Forward to Friend ...Comments...
-
Republicans to publicize pharma industry's Obamacare deal
Read More ...Forward to Friend ...Comments...
-
Roche's Zelboraf cuts 12 mon melanoma death risk by 38%
Read More ...Forward to Friend ...Comments...
-
Tolerability of Aveo/Astellas' tivozanib impresses in kidney Ca
Read More ...Forward to Friend ...Comments...
-
Array shares rise on lung Ca, melanoma data for selumetinib
Read More ...Forward to Friend ...Comments...
-
ASCO 2012 abstract data dump: Cancer stocks in focus
Read More ...Forward to Friend ...Comments...
-
Computer Sciences posts loss due to UK NHS HIT contract
Read More ...Forward to Friend ...Comments...
-
EU Parliament seeks urgent review of drug monitoring
Read More ...Forward to Friend ...Comments...
-
Express Scripts to settle charges over controlled drug thefts
Read More ...Forward to Friend ...Comments...
-
FCC chooses spectrum for wireless medical devices
Read More ...Forward to Friend ...Comments...
-
FDA warning on NJ mfrg plant hurts Hikma margins on generics
Read More ...Forward to Friend ...Comments...
-
House panel's 'classic pursuit' of Pfizer, PhRMA execs on 'the deal'
Read More ...Forward to Friend ...Comments...
-
J&J "very serious" about acquiring CNS & Ca assets in China
Read More ...Forward to Friend ...Comments...
-
Pharmageddon continues: Plavix exclusivity ends Thursday
Read More ...Forward to Friend ...Comments...
-
Piramal gets Manhattan Research in $365M Dec Resources buy
Read More ...Forward to Friend ...Comments...
-
Targeted Ca drugs with punch: The next big class of antibodies
Read More ...Forward to Friend ...Comments...
-
Alliance Boots defends taxes paid; Eyes M&A exit strategy
Read More ...Forward to Friend ...Comments...
-
Amgen revives rilotumumab on data for high c-Met gastric Ca
Read More ...Forward to Friend ...Comments...
-
Basics of biz: With risk-shift, providers face collection challenges
Read More ...Forward to Friend ...Comments...
-
Complex universe of patent litigation: "Sport of kings"
Read More ...Forward to Friend ...Comments...
-
Consumer Reports: Long-term benefit of ADHD drugs uncertain
Read More ...Forward to Friend ...Comments...
-
Embedded chips, GPS pacemakers.. what's in our health future?
Read More ...Forward to Friend ...Comments...
-
FDA reviews drugs quite quickly, thank you
Read More ...Forward to Friend ...Comments...
-
GSK's dabrafenib/trametinib cocktail slows melanoma w/ less tox
Read More ...Forward to Friend ...Comments...
-
Money, matrices & analytics: Why ACOs may be different
Read More ...Forward to Friend ...Comments...
-
Pfizer's Torisel can't beat Bayer's Nexavar in renal cell Ca
Read More ...Forward to Friend ...Comments...
-
Shareholder proposals for lobbying disclosure fail @ WellPoint
Read More ...Forward to Friend ...Comments...
-
US PEPFAR HIV aid has prevented 741K Africa deaths @ $27 per
Read More ...Forward to Friend ...Comments...
-
50-nation, Global Research Council announced after NSF mtg
Read More ...Forward to Friend ...Comments...
-
Abbott's Xience wins shortest duration of anti-platelet Tx, 3 mos
Read More ...Forward to Friend ...Comments...
-
Almost divine intervention: Robotic limbs controlled by thoughts
Read More ...Forward to Friend ...Comments...
-
Are arrogant docs & scary regs keeping techies out of health?
Read More ...Forward to Friend ...Comments...
-
Big data analytics coming to life sciences; But they're not here yet
Read More ...Forward to Friend ...Comments...
-
Biotech career progression opportunities much different today
Read More ...Forward to Friend ...Comments...
-
Cardinal DEA deal calls for 2-yr controlled drug shipping halt
Read More ...Forward to Friend ...Comments...
-
China FDA approves Baxter's Advate, Factor VIII in hemophilia
Read More ...Forward to Friend ...Comments...
-
Copyright decision favors nonprofit institutions vs publishers
Read More ...Forward to Friend ...Comments...
-
Court to hear appeal of dismissal of PA Risperdal suit v. J&J
Read More ...Forward to Friend ...Comments...
-
Critics say fed agency should oversee DSM's shilling for pharma
Read More ...Forward to Friend ...Comments...
-
Data-mining in doctor's office helps solve medical mysteries
Read More ...Forward to Friend ...Comments...
-
Early signs of Parkinson's alpha-synuclein may be seen in colon
Read More ...Forward to Friend ...Comments...
-
Elavation: EP-101's Ph 2b, new nebulizer 'gold standard' in COPD
Read More ...Forward to Friend ...Comments...
-
Endo leads pharma's revived interest in device combination devt
Read More ...Forward to Friend ...Comments...
-
Ex-BMS exec ordered by judge to write a book... is finished
Read More ...Forward to Friend ...Comments...
-
FDA panel backs OraSure's in-home HIV test; Retail under $60
Read More ...Forward to Friend ...Comments...
-
GE's 2 & 1/2 year-old, $250M VC fund still has 'lot of dry powder'
Read More ...Forward to Friend ...Comments...
-
Genes are overrated, genetics is underrated
Read More ...Forward to Friend ...Comments...
-
Get what u pay for: UK drug shortages arise from parallel trade
Read More ...Forward to Friend ...Comments...
-
GSK buys remaining 80% of Cellzome, proteomics tech for $98M
Read More ...Forward to Friend ...Comments...
-
HHS launches national trend, health indicator comparison tool
Read More ...Forward to Friend ...Comments...
-
Hmmm.. SAC Cap bought 1.2M Ardea shrs before $1.3B AZ buy
Read More ...Forward to Friend ...Comments...
-
If there are no standards for peer review, what's it worth?
Read More ...Forward to Friend ...Comments...
-
International groups push patent pool to solve funding problems
Read More ...Forward to Friend ...Comments...
-
Last lecturer's spouse: "Dream New Dreams... a new life"
Read More ...Forward to Friend ...Comments...
-
Lessons from the front line of health care delivery reform
Read More ...Forward to Friend ...Comments...
-
Mayo: 10 recs to close credibility gap in medical research
Read More ...Forward to Friend ...Comments...
-
Mgd care will req multi-TNF failures before Pfizer's tofacitinib
Read More ...Forward to Friend ...Comments...
-
Mobile app focuses on better patient 'handoffs' to cut errors
Read More ...Forward to Friend ...Comments...
-
Mologen's MGN1703 extends PFS twofold in colorectal Ca
Read More ...Forward to Friend ...Comments...
-
Nanofluid device detects, sorts molecules by epigenetic state
Read More ...Forward to Friend ...Comments...
-
New drug trial seeks to stop Alzheimer's before it starts
Read More ...Forward to Friend ...Comments...
-
NICE u-turns to fund Zytiga in prostate Ca after J&J discounts
Read More ...Forward to Friend ...Comments...
-
No options? Ahead of IPO, GM to quit advertising on Facebook
Read More ...Forward to Friend ...Comments...
-
Northwest Bio's DCVax doubles survival time in glioblastoma
Read More ...Forward to Friend ...Comments...
-
Pfizer, BMS, Merck, Sanofi, Takeda, Roche & AZ bid for Amylin
Read More ...Forward to Friend ...Comments...
-
Piramal to buy Decision Resources for about $635M
Read More ...Forward to Friend ...Comments...
-
Prolor nets $35M in public offering for long-acting biobetters
Read More ...Forward to Friend ...Comments...
-
Promedior's Shire vet CEO takes its $22M from Philly to Boston
Read More ...Forward to Friend ...Comments...
-
Ra Pharma gets $8.6M; Unveils HAE as lead for cyclomimetics
Read More ...Forward to Friend ...Comments...
-
Roche seeks to show its pipeline can protect oncology franchise
Read More ...Forward to Friend ...Comments...
-
Roche's crenezumab picked for asymptomatic Alzheimer's trial
Read More ...Forward to Friend ...Comments...
-
UK's NICE delays access to new cancer drugs for years
Read More ...Forward to Friend ...Comments...
-
US biosimilars law is 2 yrs old & FDA has yet to receive an app
Read More ...Forward to Friend ...Comments...
-
WHO warns of HTN, diabetes, obesity spread to poor nations
Read More ...Forward to Friend ...Comments...
-
$1 Trillion in revenue at stake for insurers in SCOTUS' ACA ruling
Read More ...Forward to Friend ...Comments...
-
A brief history of Pfizer's JAK inhibitor, tofacitinib
Read More ...Forward to Friend ...Comments...
-
Achillion's mid-stage ACH-3102 gets FDA fast track in hep C
Read More ...Forward to Friend ...Comments...
-
ADHD behavioral therapy may be more effective than drugs
Read More ...Forward to Friend ...Comments...
-
Agencies going after Accenture, Deloitte's IT, CRM biz
Read More ...Forward to Friend ...Comments...
-
Alzheimers.gov: US launches Alzheimer's plan & research push
Read More ...Forward to Friend ...Comments...
-
AstraZeneca antitrust fine should stand, says EU court aide
Read More ...Forward to Friend ...Comments...
-
AstraZeneca slashes 400 more jobs in Sweden
Read More ...Forward to Friend ...Comments...
-
Can whole genome sequencing contribute to clinical care?
Read More ...Forward to Friend ...Comments...
-
Cardinal facility suspended under DEA settlement
Read More ...Forward to Friend ...Comments...
-
Change.org petition demands US price cut for Novartis' Gleevec
Read More ...Forward to Friend ...Comments...
-
Cornerstone acquires EKR Therapeutics, acute-care hosp prods
Read More ...Forward to Friend ...Comments...
-
Digital health oversold: Pills still matter and so does biology
Read More ...Forward to Friend ...Comments...
-
Drugmakers choose faster trial recruiting over CRO cost cuts
Read More ...Forward to Friend ...Comments...
-
Ex-Accenture exec: Microsoft Windows anology for pharma woes
Read More ...Forward to Friend ...Comments...
-
FDA again cautions on Novartis' Gilenya, the only oral MS drug
Read More ...Forward to Friend ...Comments...
-
FDA, saccharin, me and maybe the mafia - A true story
Read More ...Forward to Friend ...Comments...
-
Financial incentives for feeding tubes lead to dementia in elderly
Read More ...Forward to Friend ...Comments...
-
Five questions for E&Y's exec on the future of health IT
Read More ...Forward to Friend ...Comments...
-
Florida pill mill doctor: "I was driven by greed"
Read More ...Forward to Friend ...Comments...
-
Health insurance expansion heats up primary care turf battle
Read More ...Forward to Friend ...Comments...
-
Hospira hydromorphone recall due to overfill volume issue
Read More ...Forward to Friend ...Comments...
-
Locating American mfrg: Trends in geography of production
Read More ...Forward to Friend ...Comments...
-
Lundbeck's data support Lu AA21004 depression filing in 2012
Read More ...Forward to Friend ...Comments...
-
Mixed reviews, reservations abound for FDA Rx-to-OTC proposal
Read More ...Forward to Friend ...Comments...
-
Private equity firms buy half of Italian generic mfr, Rottapharm
Read More ...Forward to Friend ...Comments...
-
Rising opioid addiction is a problem that can be solved
Read More ...Forward to Friend ...Comments...
-
St Jude gets EU approval for HTN device; Tiny renal nerve scars
Read More ...Forward to Friend ...Comments...
-
St Jude hopes slow & steady wins renal denervation race in HTN
Read More ...Forward to Friend ...Comments...
-
The Atlantic: Mortal struggles; the making of a cancer doctor
Read More ...Forward to Friend ...Comments...
-
Towers pays $435M for #1 US Medicare exchange, Extend Health
Read More ...Forward to Friend ...Comments...
-
UK lawmakers urge action on medicine shortages
Read More ...Forward to Friend ...Comments...
-
Arena & Eisai broaden mktg deal for Lorquess in weight-loss
Read More ...Forward to Friend ...Comments...
-
ASCO preview: 8 cancer drugs to watch at the big show
Read More ...Forward to Friend ...Comments...
-
ASCO: 7 Cancer drug stocks to know right now
Read More ...Forward to Friend ...Comments...
-
Athersys-Pfizer to wrap up IBD Ph 2 for MultiStem drug in 2012
Read More ...Forward to Friend ...Comments...
-
Beat odds at judging risk with fast, clear feedback -Like weather
Read More ...Forward to Friend ...Comments...
-
BioAlliance starts Ph 3 for Livatag in primary liver Ca
Read More ...Forward to Friend ...Comments...
-
Cardinal Health to buy Chicago distributor, Dik Drug
Read More ...Forward to Friend ...Comments...
-
Employers still shifting more of all health costs to workers
Read More ...Forward to Friend ...Comments...
-
Even for Stanford geneticist, applying gene sequencing is tough
Read More ...Forward to Friend ...Comments...
-
Ex-pharma CEO finds success @ very different Smith & Nephew
Read More ...Forward to Friend ...Comments...
-
FDA concept would mean fewer prescriptions, more OTCs
Read More ...Forward to Friend ...Comments...
-
FDA eases biologic sterility test reqs to back state-of-art analyses
Read More ...Forward to Friend ...Comments...
-
FDA grants fast track for Ohr's squalamine drops in wet-AMD
Read More ...Forward to Friend ...Comments...
-
FDA puts new limits on Novartis Gilenya on addl 1st dose death
Read More ...Forward to Friend ...Comments...
-
Furiex: J&J returns global rights to Priligy in premature ejac
Read More ...Forward to Friend ...Comments...
-
Good world health data rare; Extrapolation brings danger
Read More ...Forward to Friend ...Comments...
-
GSK gets FDA approval for acne treatment, Fabior Foam
Read More ...Forward to Friend ...Comments...
-
Marken considers shipping trial drugs direct to patient homes
Read More ...Forward to Friend ...Comments...
-
Maxygen earns $30M from Bayer for recombinant factor VIIa
Read More ...Forward to Friend ...Comments...
-
Meddik: Docs have clinical knowledge; pats, practical knowledge
Read More ...Forward to Friend ...Comments...
-
Nanoparticles deliver high doses of antibiotics directly to bacteria
Read More ...Forward to Friend ...Comments...
-
No better example of industry influence than opioid epidemic
Read More ...Forward to Friend ...Comments...
-
Novo Nordisk initiates share repurchase program
Read More ...Forward to Friend ...Comments...
-
Ono, Paion win in Ph 2 for ONO-2745/CNS 7056 in general anesthesia
Read More ...Forward to Friend ...Comments...
-
Opko's Alzheimer's blood diagnostic expected launch in 2013
Read More ...Forward to Friend ...Comments...
-
Pharma digital dreamers have forgotten some key principles
Read More ...Forward to Friend ...Comments...
-
Roche applies Ca drug devt skills to Alzheimer's & autism
Read More ...Forward to Friend ...Comments...
-
Sanofi plan for Shantha Biotech gets Indian govt approval
Read More ...Forward to Friend ...Comments...
-
Sanofi workers suspend strike, pending agreement on conditions
Read More ...Forward to Friend ...Comments...
-
Servier & founder on trial for 500 deaths assoc w/ Mediator
Read More ...Forward to Friend ...Comments...
-
Ventrus' diltiazem cream (VEN 307) wins in anal fissures Ph 3
Read More ...Forward to Friend ...Comments...
-
Vertex rises as JP Morgan ups rating on cystic fibrosis drugs
Read More ...Forward to Friend ...Comments...
-
23andMe eliminates subscription model - Single $299 price
Read More ...Forward to Friend ...Comments...
-
2M cases of cancer a year due to H pylori, Hep B&C and/or HPV
Read More ...Forward to Friend ...Comments...
-
5-year study seeks definitive answers on proton beams vs radiation
Read More ...Forward to Friend ...Comments...
-
85% of docs own or use a smartphone for professional purposes
Read More ...Forward to Friend ...Comments...
-
Aastrom's autologous stem cell Tx improves dilated cardiomyopathy
Read More ...Forward to Friend ...Comments...
-
Abbott escapes a long-running GMP consent decree
Read More ...Forward to Friend ...Comments...
-
Abbott faces another battle over Kaletra HIV med in Malaysia
Read More ...Forward to Friend ...Comments...
-
Abbott petitions FDA to deny biosimilar apps for BLA approvals prior to March 23, 2010 enactment of BPCIA
Read More ...Forward to Friend ...Comments...
-
Adderral: It's like taking meth, only this is..prescribed by a doctor,
Read More ...Forward to Friend ...Comments...
-
Alliance Boots gloomy on UK economic outlook
Read More ...Forward to Friend ...Comments...
-
Almost 1 in 3 in US sleepwalk at some point in their lives
Read More ...Forward to Friend ...Comments...
-
Alnylam's RNAi drug ALN-TTR01 cuts serum transthyretin protein levels
Read More ...Forward to Friend ...Comments...
-
AMA not smiling over FTC teeth whitening ruling it contends could impede states' medical practice regs
Read More ...Forward to Friend ...Comments...
-
AMAG Pharma is no longer considering a sale; Shares fall
Read More ...Forward to Friend ...Comments...
-
AmerisourceBergen names new finance chief
Read More ...Forward to Friend ...Comments...
-
Amgen to testify @ FDA biosimilars stakeholder hearing
Read More ...Forward to Friend ...Comments...
-
Amylin attracting M&A queries from AstraZeneca, Pfizer & Sanofi
Read More ...Forward to Friend ...Comments...
-
Animal rights activist's conviction stands for comparing Vasella to Hitler
Read More ...Forward to Friend ...Comments...
-
Anti-vax crew takes toll: Whooping cough epidemic in WA state
Read More ...Forward to Friend ...Comments...
-
Arena news boosts Orexigen, Vivus shares
Read More ...Forward to Friend ...Comments...
-
Arena rockets on FDA panel nod; Orexigen & Vivus up
Read More ...Forward to Friend ...Comments...
-
Arena shares up more than 90% in after-hours trading
Read More ...Forward to Friend ...Comments...
-
Army clinical trials to evaluate antipsychotic use in PTSD
Read More ...Forward to Friend ...Comments...
-
Arno Therapeutics gets EU orphan designation for AR-42 in neurofibromatosis type 2
Read More ...Forward to Friend ...Comments...
-
As US argues over health care, nations embrace global coverage
Read More ...Forward to Friend ...Comments...
-
BASi plans more cost cutting as toxicology testing demand slips
Read More ...Forward to Friend ...Comments...
-
Bayer: Cipla breached patent rights by cutting Nexavar price
Read More ...Forward to Friend ...Comments...
-
Berwick on health spending: 'We have to improve our way out of this'
Read More ...Forward to Friend ...Comments...
-
Big data and public health: Reducing unwarranted services
Read More ...Forward to Friend ...Comments...
-
Big pharma could face new scrutiny in US after India report
Read More ...Forward to Friend ...Comments...
-
Big pharma is outsourcing skills that will be critical in future
Read More ...Forward to Friend ...Comments...
-
Bill Cowher fronts BMS-backed 'Melanoma Exposed' awareness campaign
Read More ...Forward to Friend ...Comments...
-
Bill that would help curb drug shortages headed for vote
Read More ...Forward to Friend ...Comments...
-
Biogen launches two new dosing innovations for once-a-week Avonex in relapsing MS
Read More ...Forward to Friend ...Comments...
-
Biogen submissions for BG-12 in MS accepted by EMA & FDA
Read More ...Forward to Friend ...Comments...
-
Bionor & Eurocine's Vacc-4x, nasal HIV vax is immunogenic
Read More ...Forward to Friend ...Comments...
-
Biotech and other life sciences companies flourish in Vienna
Read More ...Forward to Friend ...Comments...
-
Biotech is about accepting that unit of production is living cell
Read More ...Forward to Friend ...Comments...
-
Burrill: Health care today essentially same as 2000 years ago
Read More ...Forward to Friend ...Comments...
-
Canadian hearing for Chantix class-action suit nears
Read More ...Forward to Friend ...Comments...
-
Cancer Genetics plans to go public with $48M IPO
Read More ...Forward to Friend ...Comments...
-
Cardinal bows to US DEA's fight vs opioid abuse
Read More ...Forward to Friend ...Comments...
-
Cardinal Health set for DEA showdown over pain pill sales
Read More ...Forward to Friend ...Comments...
-
Carecloud helps urgent care centers provide immediate assessment and management of sports injuries
Read More ...Forward to Friend ...Comments...
-
CBER Strategic Plan for Regulatory Science & Research 2012-16
Read More ...Forward to Friend ...Comments...
-
CDC: National ALS Registry collects info to help scientists learn more about ALS
Read More ...Forward to Friend ...Comments...
-
Cell Therapeutics gets conditional marketing auth from European Commission for pixantrone in NHL
Read More ...Forward to Friend ...Comments...
-
Cephalon CEO and R&D chief leave Teva
Read More ...Forward to Friend ...Comments...
-
CHI/BCG: Differences in FDA performance by therapeutic area
Read More ...Forward to Friend ...Comments...
-
CMS adds adv practice nurses, pharmacists to 'medical staff'
Read More ...Forward to Friend ...Comments...
-
Cold-chain services to be $7.6B biz in 2013 & $8.9B in 2016
Read More ...Forward to Friend ...Comments...
-
Contract mfr sees US trend in repatriating device mfrg
Read More ...Forward to Friend ...Comments...
-
Could pre-emptive treatment lead to higher HIV infection rates?
Read More ...Forward to Friend ...Comments...
-
Counterfeit or substandard? The role of regulation and distribution channel in drug safety
Read More ...Forward to Friend ...Comments...
-
Diabetes care in England in a 'state of crisis'
Read More ...Forward to Friend ...Comments...
-
Digital collaboration helps docs counter Sunshine Act flaws
Read More ...Forward to Friend ...Comments...
-
Disincentive: Shouldn't EPO & blood Txs been balanced long ago?
Read More ...Forward to Friend ...Comments...
-
Doctors pressured to write OTC Rxs for HSA reimbursement
Read More ...Forward to Friend ...Comments...
-
Drug makers working on emergency supply plan in Greece
Read More ...Forward to Friend ...Comments...
-
EU Alliance for Access to Safe Meds calls for urgent action to clarify when drugs can be used off-label
Read More ...Forward to Friend ...Comments...
-
EU court blocks L'Oreal's trademarks similar to Allergan's Botox
Read More ...Forward to Friend ...Comments...
-
Express Scripts: 2012 profits could miss Wall Street's target
Read More ...Forward to Friend ...Comments...
-
Express Scripts: Specialty drug costs a major employer worry
Read More ...Forward to Friend ...Comments...
-
Facebook to sell apps through new online hub
Read More ...Forward to Friend ...Comments...
-
False choice between Dem's 'fed-centic' & GOP's 'leave it to states'
Read More ...Forward to Friend ...Comments...
-
FDA adv panel backs Gilead's HIV 'Quad' in HIV too
Read More ...Forward to Friend ...Comments...
-
FDA adv panel backs Gilead's Truvada for HIV prevention
Read More ...Forward to Friend ...Comments...
-
FDA advisers rec approval of Arena's diet drug, lorcaserin
Read More ...Forward to Friend ...Comments...
-
FDA approves BMS' new Orencia biologic mfrg facility in MA
Read More ...Forward to Friend ...Comments...
-
FDA issues final rule on sterility testing of biologics; Many steps eliminated
Read More ...Forward to Friend ...Comments...
-
FDA rule would req new medical imaging devices to include pediatric dose settings & instructions
Read More ...Forward to Friend ...Comments...
-
FDA tackles 'public health implications' of in-home HIV test
Read More ...Forward to Friend ...Comments...
-
FDA warns Acorda over averse event reporting
Read More ...Forward to Friend ...Comments...
-
FDA warns MS patients on risky, unproven CCSVI angioplasty
Read More ...Forward to Friend ...Comments...
-
Fed appeals court upholds $21.6M NH verdict v. Mutual Pharma
Read More ...Forward to Friend ...Comments...
-
Federal investigators urge stronger oversight of Medicare Part D
Read More ...Forward to Friend ...Comments...
-
Ferring's Lysteda reduces heavy menstrual flow
Read More ...Forward to Friend ...Comments...
-
Fibrocell raises $3M for personalized cell therapy wrinkle treatments
Read More ...Forward to Friend ...Comments...
-
Fibrocell submits Ph 2 protocol for azficel-T in restrictive burn
Read More ...Forward to Friend ...Comments...
-
FINRA warns of nutraceutical "pump and dump" scams
Read More ...Forward to Friend ...Comments...
-
Forbes: The rebates that ate AZ - Secret world of drug rebates
Read More ...Forward to Friend ...Comments...
-
Francis Collins 'supersizes' obesity documentary on Colbert
Read More ...Forward to Friend ...Comments...
-
Fresenius plans to raise $1.3B to fund Rhoen Klinikum purchase
Read More ...Forward to Friend ...Comments...
-
FTC & Skechers settle toning shoe claims case for $40M
Read More ...Forward to Friend ...Comments...
-
Galectin opens Ph 1/2 for GM-CT-01 & vax combo in melanoma
Read More ...Forward to Friend ...Comments...
-
GenDX gets non-exclusive global rights to distribute Qiagen's LongRange PCR kit
Read More ...Forward to Friend ...Comments...
-
Gene therapy helps children paralyzed by AADC, brain disease
Read More ...Forward to Friend ...Comments...
-
Generic drug labeling carve-out citizen petition scorecard
Read More ...Forward to Friend ...Comments...
-
Generic Lipitor could eventually save NHS a whopping $566M/year
Read More ...Forward to Friend ...Comments...
-
Germany's IQWiG backs BMS' Yervoy for melanoma
Read More ...Forward to Friend ...Comments...
-
Giffen Solutions app, created by fed-up doc, connects MDs and patients
Read More ...Forward to Friend ...Comments...
-
Gilead's crucial AIDS "Quad" pill gets thumbs up
Read More ...Forward to Friend ...Comments...
-
GLP-1s may yet be 21st century's top development in diabetes
Read More ...Forward to Friend ...Comments...
-
GM to stop advertising on Facebook; Paid ads have little impact
Read More ...Forward to Friend ...Comments...
-
Goldman Sachs upgrades Incyte on Jakafi, pipeline and M&A
Read More ...Forward to Friend ...Comments...
-
Google's Sergey Brin making progress in Parkinson's quest
Read More ...Forward to Friend ...Comments...
-
GSK lifts its Theravance stake to 26.7%
Read More ...Forward to Friend ...Comments...
-
GSK needs to add just a little bit more to Human Genome bid
Read More ...Forward to Friend ...Comments...
-
GSK says it received India trials waiver for ambrisentan in PAH
Read More ...Forward to Friend ...Comments...
-
Harvard Alzheimer's research scientific fraud case set for trial
Read More ...Forward to Friend ...Comments...
-
Health plans don't always play hardball with providers
Read More ...Forward to Friend ...Comments...
-
HHS moves to streamline reporting, update e-prescribing reqs
Read More ...Forward to Friend ...Comments...
-
HHS' National Plan to Address Alzheimer's Disease
Read More ...Forward to Friend ...Comments...
-
Humira on solid ground, analysts say, despite Pfizer's JAK
Read More ...Forward to Friend ...Comments...
-
I love my job - I run FDA's China Office - How do you engage a regs counterpart that has export promotion as a primary mission?
Read More ...Forward to Friend ...Comments...
-
IDRI, Aeras team up to develop tuberculosis vaccine
Read More ...Forward to Friend ...Comments...
-
If ACA didn't include exchanges, there'd be more up & running
Read More ...Forward to Friend ...Comments...
-
Improving market analyses with social strategy at 3M
Read More ...Forward to Friend ...Comments...
-
India vows reforms after probe slams approval process
Read More ...Forward to Friend ...Comments...
-
Indian minister complains of anti-generics smear campaign
Read More ...Forward to Friend ...Comments...
-
Inovio's universal avian flu vax generates protective antibodies vs 6 H5N1 viruses in Ph 1
Read More ...Forward to Friend ...Comments...
-
Iressa overreaction? 65% of AZ's pipeline is personalized med
Read More ...Forward to Friend ...Comments...
-
Irish universities lead statin trials for lung failure
Read More ...Forward to Friend ...Comments...
-
Is GSK more interested in HGSI's darapladib than it's letting on?
Read More ...Forward to Friend ...Comments...
-
Is this patient privacy crusader doing more harm than good?
Read More ...Forward to Friend ...Comments...
-
J&J and Medtronic M&A strategies contrast. Can both win?
Read More ...Forward to Friend ...Comments...
-
JAMA: Two sets of experts, two opinions on statins in primary prevention
Read More ...Forward to Friend ...Comments...
-
Juventas recruiting Ph 2a for regenerative JVS-100 in critical limb ischemia
Read More ...Forward to Friend ...Comments...
-
Kaiser: Wide variance in Medicare hosp bills, even in same city
Read More ...Forward to Friend ...Comments...
-
Korean drugmakers jostle for generic Viagra market
Read More ...Forward to Friend ...Comments...
-
Lap Band surgery center owners accused of ID theft, false billing
Read More ...Forward to Friend ...Comments...
-
Lethal problem with St Jude heart device could be widespread
Read More ...Forward to Friend ...Comments...
-
Lilly and Abbott win sales rep overtime case
Read More ...Forward to Friend ...Comments...
-
Lilly shifts spotlight to diabetes pipeline
Read More ...Forward to Friend ...Comments...
-
Lilly: Forget Alzheimer's; think diabetes
Read More ...Forward to Friend ...Comments...
-
Main driver for seeking online health information is privacy
Read More ...Forward to Friend ...Comments...
-
Many psychs believe DSM-5 revisions should be shelved for year
Read More ...Forward to Friend ...Comments...
-
McMaster study: Cardiac ablation more effective than afib drugs
Read More ...Forward to Friend ...Comments...
-
Medco wins CBI's 11th annual Forum on Patient Adherence for pharmacist counseling?
Read More ...Forward to Friend ...Comments...
-
Medecins Sans Frontieres: "Key challenges...glossed over" in vax initiative
Read More ...Forward to Friend ...Comments...
-
Medgenics gets FDA OK for Ph 2b of Epodure in dialysis anemia
Read More ...Forward to Friend ...Comments...
-
Medical boards' actions against docs up 6.8% in 2011
Read More ...Forward to Friend ...Comments...
-
Medical Publishing Insights and Practices Initiative: Restoring credibility of industry-sponsored clinical research
Read More ...Forward to Friend ...Comments...
-
Merck isn't liable for Vioxx heart risks says Australia's top court
Read More ...Forward to Friend ...Comments...
-
Merck KGgA committed to big cost cutting as profits fall
Read More ...Forward to Friend ...Comments...
-
Merck Serono workers threaten to strike over layoffs
Read More ...Forward to Friend ...Comments...
-
Moody's: Non-profit US hospitals to do more with less
Read More ...Forward to Friend ...Comments...
-
More than a third of prescriptions now electronic
Read More ...Forward to Friend ...Comments...
-
Most genetic variations rare, recent, make drug discovery tough
Read More ...Forward to Friend ...Comments...
-
MultiCell: Preclinical data supports MCT-465 & MCT-485 in primary liver Ca
Read More ...Forward to Friend ...Comments...
-
Mylan launches generic Lipitor in France, UK
Read More ...Forward to Friend ...Comments...
-
Nasal steroids not much help in acute sinusitis
Read More ...Forward to Friend ...Comments...
-
NEJM: Consider risks, benefits of long-term bisphosphonate use
Read More ...Forward to Friend ...Comments...
-
Nephromics grants pre-eclampsia assay rights to Thermo Fisher
Read More ...Forward to Friend ...Comments...
-
New Zealand drugmakers deny plans to undermine Pharmac
Read More ...Forward to Friend ...Comments...
-
Newron wins in safinamide Ph 3 for Parkinson's; Signs deal with Zambon
Read More ...Forward to Friend ...Comments...
-
NicOx rises on 1Q12 financials for the first quarter and revealed plans for more ophthalmology acquisitions
Read More ...Forward to Friend ...Comments...
-
NIH: Celgene's Revlimid lengthens myeloma PFS at cost of 2x risk of second Ca's
Read More ...Forward to Friend ...Comments...
-
No DDMAC for new cholesterol Android app
Read More ...Forward to Friend ...Comments...
-
No surprise: Patients are bottleneck in healthcare IT
Read More ...Forward to Friend ...Comments...
-
Not retiring at 65: Physician goes from anti-EHR to pro-ACO
Read More ...Forward to Friend ...Comments...
-
NovaDigm's looks to take single antigen vax vs fungal & bacterial infection to Ph 2
Read More ...Forward to Friend ...Comments...
-
Novartis launches Hecoria, branded generic for Astellas' Prograf
Read More ...Forward to Friend ...Comments...
-
Novartis to probe Indian drug approval allegations
Read More ...Forward to Friend ...Comments...
-
Novartis: Our people prefer internal courses to business schools
Read More ...Forward to Friend ...Comments...
-
Novartis: Pasireotide beats Sandostatin in achromegaly
Read More ...Forward to Friend ...Comments...
-
NuMe focuses on good gut bacteria to help prevent T2D
Read More ...Forward to Friend ...Comments...
-
Nurse practitioners say TX should cut unneeded limits on Rx powers
Read More ...Forward to Friend ...Comments...
-
OIG uncovers flaws in CMS processes, programs
Read More ...Forward to Friend ...Comments...
-
Omnicare settles DoJ controlled substance probe for $50M
Read More ...Forward to Friend ...Comments...
-
OncoMed Pharma files for $115M IPO for Ca mABs
Read More ...Forward to Friend ...Comments...
-
Onconova raises $7M for Rigosertib in myelodysplastic syndromes
Read More ...Forward to Friend ...Comments...
-
OR Health & Science Univ breed mouse model of ADHD
Read More ...Forward to Friend ...Comments...
-
Over 2600 pharmacies have suspicious/excessive CMS billing
Read More ...Forward to Friend ...Comments...
-
PA judges hear arguments in Risperdal case
Read More ...Forward to Friend ...Comments...
-
Patients having St Jude defibrillators removed just in case
Read More ...Forward to Friend ...Comments...
-
Pfizer cuts 50 jobs at Canadian estrogen facility
Read More ...Forward to Friend ...Comments...
-
Pfizer distribution policy criticized by Australian wholesaler
Read More ...Forward to Friend ...Comments...
-
Pfizer to eliminate its defined benefit pension plan
Read More ...Forward to Friend ...Comments...
-
Pfizer's Quigley unit to continue its 8-year asbestos bankruptcy
Read More ...Forward to Friend ...Comments...
-
Pharma, device firms kill CoI rule, win accelerated approval
Read More ...Forward to Friend ...Comments...
-
Plaintiffs hardly ever win malpractice cases going to jury
Read More ...Forward to Friend ...Comments...
-
PolyMedix ends trials for PMX-60056 in anticoagulant reversal
Read More ...Forward to Friend ...Comments...
-
Preclinical services firm, SNBL claims to have fixed troubled facility
Read More ...Forward to Friend ...Comments...
-
PREX2 gene frequently mutated & functional in melanomas
Read More ...Forward to Friend ...Comments...
-
Progress made on Medicare's perpetual 'doc fix'
Read More ...Forward to Friend ...Comments...
-
Promedior moves fibrosis pipeline to Boston; Hires Shire vet as CEO
Read More ...Forward to Friend ...Comments...
-
Propofol: The economics of a generic injectable supply problem
Read More ...Forward to Friend ...Comments...
-
Protesting scientists deliver coffin to Downing Street
Read More ...Forward to Friend ...Comments...
-
Public Citizen: Ranking of State Medical Boards on doc discipline
Read More ...Forward to Friend ...Comments...
-
Pulmotect wins $7.1M to advance PUL-042 against chemo infection
Read More ...Forward to Friend ...Comments...
-
Reimbursement support services will be critical for biosimilars
Read More ...Forward to Friend ...Comments...
-
Relatively passive approach to drug benefit continues in Canada
Read More ...Forward to Friend ...Comments...
-
ReNeuron on track for Ph 2 of ReN001 in disabled stroke patients "during the course of next year"
Read More ...Forward to Friend ...Comments...
-
Researchers duel over Chantix and heart risks
Read More ...Forward to Friend ...Comments...
-
Retail health clinics grow in popularity
Read More ...Forward to Friend ...Comments...
-
Rib-X Pharma postpones IPO after cutting price by 50%
Read More ...Forward to Friend ...Comments...
-
Ropack expands solid dose contract packaging services facility
Read More ...Forward to Friend ...Comments...
-
Rosetta Genomics to raise $2.2M for mRNA molecular assays
Read More ...Forward to Friend ...Comments...
-
Science vs PR: How work is turned into patently junk science
Read More ...Forward to Friend ...Comments...
-
Scottish Med Consortium approves Pfizer's Xiaflex on NHS for Dupuytren's
Read More ...Forward to Friend ...Comments...
-
Silence posts Ph 1 data for Atu027 in neuroendocrine cancers
Read More ...Forward to Friend ...Comments...
-
South Korea: Chinese-made 'health' pills contain human remains
Read More ...Forward to Friend ...Comments...
-
Suppression of creativity in academic labs squelches innovation
Read More ...Forward to Friend ...Comments...
-
Symphony Tech, private equity firm acquires the Wolters Kluwer health analytics biz
Read More ...Forward to Friend ...Comments...
-
Takeda falls most in 14 mos on 40% profit forecast drop
Read More ...Forward to Friend ...Comments...
-
Takeda investing in Juventas' next regenerative med round
Read More ...Forward to Friend ...Comments...
-
Takeda looking for BRIC growth: FY12-14 Mid-Range Plan
Read More ...Forward to Friend ...Comments...
-
Takeda: Vedolizumab spurs resistant Chron's remission in Ph 3
Read More ...Forward to Friend ...Comments...
-
Taxing times for French pharma under radical health reforms
Read More ...Forward to Friend ...Comments...
-
The new study buddy: Adderall, Ritalin, Dexadrine, Concerta and the like
Read More ...Forward to Friend ...Comments...
-
Topotarget posts Ph 1 data on belinostat in thymic carcinoma
Read More ...Forward to Friend ...Comments...
-
UK's MHRA faces 'serious lessons' from PIP scandal
Read More ...Forward to Friend ...Comments...
-
UK's NICE backs Allergan's Botox for some migraine pats
Read More ...Forward to Friend ...Comments...
-
UK's pharma trade group may restrict samples
Read More ...Forward to Friend ...Comments...
-
USDA asks MRI Research to rework enclosures after animal death
Read More ...Forward to Friend ...Comments...
-
Variants linked to disease risk in some groups won't explain it in others
Read More ...Forward to Friend ...Comments...
-
Venter: "We have 200T cells and the outcome of each of them is almost 100% genetically determined"
Read More ...Forward to Friend ...Comments...
-
Watson appoints McKinsey consultant to oversee Actavis acquisition
Read More ...Forward to Friend ...Comments...
-
Watson confirms challenge of Shire's patent for Lialda
Read More ...Forward to Friend ...Comments...
-
Watson confirms patent challenge to Warner Chilcott's Lo Loestrin Fe
Read More ...Forward to Friend ...Comments...
-
Watson to become 3rd-largest generics company with Actavis buy
Read More ...Forward to Friend ...Comments...
-
Web analytics tool organizes diabetics' activity, diet & GLU data
Read More ...Forward to Friend ...Comments...
-
What is Medicare 'double counting' and why are budget experts fighting over it?
Read More ...Forward to Friend ...Comments...
-
Why science is better when it's multinational - Cultural diversity
Read More ...Forward to Friend ...Comments...
-
Will CETP inhibitors, Merck's anacetrapib or Lilly's evacetrapib, survive
Read More ...Forward to Friend ...Comments...
-
Witty targets HGS with first hostile bid
Read More ...Forward to Friend ...Comments...
-
WSJ Reader Consult: To approve or not to approve lorcaserin?
Read More ...Forward to Friend ...Comments...